Institution · International Extranodal Lymphoma Study Group

Most cited papers from International Extranodal Lymphoma Study Group

International Extranodal Lymphoma Study Group

What are the most cited papers from International Extranodal Lymphoma Study Group?

The most cited paper from International Extranodal Lymphoma Study Group is "Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue" (Emanuele Zucca, Annarita Conconi, E Pedrinis et al., 2003), with 490 citations. Next come "Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report" (293) and "Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial" (173).

Published TypeFieldAccessCitations

Showing 36 of 36 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue Emanuele Zucca, Annarita Conconi, E Pedrinis et al. · Blood	17 Mar 2003	490
2	Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report Sean Aaron Grimm, José S. Pulido, Kristoph Jahnke et al. · Annals of Oncology Open access	5 Sep 2007	293
3	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial Andrés J.M. Ferreri et al. · Leukemia Open access	13 May 2022	173
4	Marginal-Zone Lymphomas Davide Rossi, Francesco Bertoni, Emanuele Zucca · New England Journal of Medicine	9 Feb 2022	163
5	MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial Andrés J.M. Ferreri et al. · The Lancet Haematology Open access	26 Jan 2021	108
6	Genetic and phenotypic attributes of splenic marginal zone lymphoma Ferdinando Bonfiglio et al. · Blood Open access	20 Oct 2021	97
7	Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma? Andrés J.M. Ferreri, Giuseppina Patrizia Dognini, Silvia Govi et al. · Journal of Clinical Oncology	7 Oct 2008	74
8	Marginal zone lymphoma: present status and future perspectives Chan Yoon Cheah, Emanuele Zucca, Davide Rossi et al. · Haematologica Open access	2022	63
9	Chlorambucil versus observation after anti‐Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial Barry W. Hancock et al. · British Journal of Haematology Open access	26 Nov 2008	60
10	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas Reem Karmali, Eva K. Kimby, Michele E. G. Ghielmini et al. · Annals of Oncology Open access	29 Nov 2017	27
11	INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL Annarita Conconi, Annalisa Chiappella, Lorella Orsucci et al. · Hematological Oncology	Jun 2021	21
12	Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group Sabrina Nicolosi Guidicelli, Armando López‐Guillermo, Umberto Falcone et al. · Hematological Oncology	21 Nov 2011	19
13	Understanding the group of peripheral T-cell lymphomas, unspecified. Emanuele Zucca, Pier Luigi Zinzani · PubMed	2005	14
14	IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL Maurizio Martelli et al. · Hematological Oncology Open access	Jun 2021	13
15	Autologous hematopoietic cell transplantation versus whole‐brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta‐analysis Narendranath Epperla, Tea Reljic, Sayan Mullick Chowdhury et al. · Hematological Oncology Review	3 Oct 2022	12
16	Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis Andrés JM Ferreri et al. · Blood	16 Nov 2008	7
17	Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials Côme Bommier, Mathilde Ruggiu, Aymeric Monégier et al. · Leukemia & lymphoma/Leukemia and lymphoma Review	24 Feb 2022	6
18	Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study. Umberto Vitolo, Emanuele Zucca, Maurizio Martelli et al. · Blood	16 Nov 2006	6
19	A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL Marco Montillo, Davide Rossi, Emanuele Zucca et al. · Hematological Oncology	Jun 2019	5
20	Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study Emilio Iannitto et al. · Haematologica Open access	14 Mar 2024	4
21	PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38) Maria Cristina Pirosa et al. · Hematological Oncology Open access	Jun 2021	4
22	S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559) Maurizio Martelli et al. · HemaSphere Open access	Aug 2023	3
23	Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial Andrés J.M. Ferreri et al. · Blood	15 Nov 2022	3
24	52 \| RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY Catherine Thiéblemont et al. · Hematological Oncology Open access	Jun 2025	2
25	Fast and Robust Segmentation of Copy Number Profiles Using Multi-Scale Edge Detection Ivo Kwee, Andrea Rinaldi, Cassio Polpo de Campos et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	2 Jun 2016	2
26	90 \| SEVEN‐YEAR FOLLOW‐UP OF THE IELSG42 “MARIETTA” PHASE II TRIAL: DURABLE REMISSIONS FOLLOWING MATRix/RICE INDUCTION AND THIOTEPA AUTOGRAFT IN SECONDARY CNS LYMPHOMA Kate Cwynarski et al. · Hematological Oncology Open access	Jun 2025	1
27	254 \| RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY Catherine Thiéblemont et al. · Hematological Oncology Open access	Jun 2025	1
28	259 \| IELSG49: A PHASE II TRIAL OF ACALABRUTINIB IN COMBINATION WITH TAFASITAMAB IN PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMAS Maria Cristina Pirosa, Markus Raderer, Stefano Luminari et al. · Hematological Oncology Open access	Jun 2025	1
29	European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies John G. Gribben et al. · HemaSphere Open access	31 Mar 2025	1
30	Tailoring treatment for MALT lymphoma patients: where do we stand now? Peter Johnson, Catherine Thiéblemont, Emanuele Zucca · Oncotarget Open access	6 Dec 2017	1
31	Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features. Riccardo Bomben et al. · Blood	20 Nov 2009	1
32	PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31) Annarita Conconi et al. · Hematological Oncology	Jun 2021	0
33	ENDPOINTS IN MARGINAL ZONE LYMPHOMAS: A SYSTEMATIC REVIEW REVEALS WIDE HETEROGENEITY ACROSS TRIALS AND CALLS FOR STANDARDIZATION Côme Bommier, Mathilde Ruggiu, Aymeric Monégier et al. · Hematological Oncology Open access	Jun 2021	0
34	SNP-Arrays Provide New Insights Into the Pathogenesis of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL). Andrea Rinaldi, Daniela Capello, Marta Scandurra et al. · Blood	20 Nov 2009	0
35	High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss?. Andrea Rinaldi, Michael Mian, Davide Rossi et al. · Blood	20 Nov 2009	0
36	Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP. Marta Scandurra et al. · Blood	20 Nov 2009	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.